Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer.
作者信息
Uehara Yuji, Hakozaki Taiki
机构信息
Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
出版信息
Transl Lung Cancer Res. 2023 Jan 31;12(1):6-10. doi: 10.21037/tlcr-22-872. Epub 2022 Dec 26.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer.
Transl Lung Cancer Res. 2023 Jan 31;12(1):6-10. doi: 10.21037/tlcr-22-872. Epub 2022 Dec 26.
2
Efficacy of immune checkpoint inhibitor therapy in patients with fusion-positive non-small-cell lung cancer.
Immunotherapy. 2021 Aug;13(11):893-904. doi: 10.2217/imt-2021-0035. Epub 2021 Jun 18.
3
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with Rearrangement.
Int J Mol Sci. 2020 Apr 9;21(7):2623. doi: 10.3390/ijms21072623.
4
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Cancer. 2019 Oct;136:45-51. doi: 10.1016/j.lungcan.2019.08.006. Epub 2019 Aug 14.
5
Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma.
Lung Cancer. 2020 Aug;146:366-369. doi: 10.1016/j.lungcan.2020.05.008. Epub 2020 May 27.
6
Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Scand J Immunol. 2021 Sep;94(3):e13087. doi: 10.1111/sji.13087. Epub 2021 Jun 13.
7
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Cancer Chemother Pharmacol. 2021 Feb;87(2):251-258. doi: 10.1007/s00280-020-04205-x. Epub 2021 Jan 4.
8
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Thorac Cancer. 2020 Jul;11(7):1927-1933. doi: 10.1111/1759-7714.13483. Epub 2020 May 18.
9
Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Cancer Chemother Pharmacol. 2020 Jan;85(1):121-131. doi: 10.1007/s00280-019-03993-1. Epub 2019 Nov 19.
10
The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Front Cell Dev Biol. 2021 Sep 28;9:745859. doi: 10.3389/fcell.2021.745859. eCollection 2021.
引用本文的文献
1
Immunotherapy Following Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients with Anaplastic Lymphoma Kinase‑Positive Non‑small Cell Lung Cancer in Japan.
Target Oncol. 2025 Jan;20(1):171-180. doi: 10.1007/s11523-024-01116-2. Epub 2024 Nov 28.
2
Increasing serum complement component 1q is associated with worse prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a single-center, retrospective study.
J Thorac Dis. 2024 May 31;16(5):3251-3259. doi: 10.21037/jtd-24-304. Epub 2024 May 24.
本文引用的文献
1
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series.
Transl Lung Cancer Res. 2022 Dec;11(12):2412-2417. doi: 10.21037/tlcr-22-329.
2
Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
J Cancer Res Clin Oncol. 2023 May;149(5):1755-1763. doi: 10.1007/s00432-022-04089-9. Epub 2022 Jun 16.
3
Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Thorac Cancer. 2022 Jun;13(11):1703-1711. doi: 10.1111/1759-7714.14448. Epub 2022 May 2.
4
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than .
Front Oncol. 2021 Dec 1;11:750657. doi: 10.3389/fonc.2021.750657. eCollection 2021.
5
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7.
6
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic -Rearranged Lung Cancers.
JTO Clin Res Rep. 2021 May 18;2(7):100187. doi: 10.1016/j.jtocrr.2021.100187. eCollection 2021 Jul.
7
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002891.
8
RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
J Thorac Oncol. 2021 May;16(5):798-806. doi: 10.1016/j.jtho.2021.01.1619. Epub 2021 Feb 12.
9
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2021 Jan;22(1):49-57. doi: 10.1016/j.cllc.2020.08.003. Epub 2020 Sep 18.
10
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated positive non-small-cell lung cancer.
Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.
Zotero 插件